Royal Philips (NYSE:PHG) announced today that it launched the Azurion Lung Edition imaging system for diagnosing and treating lung cancer.
Amsterdam-based Philips’ Azurion Lung Edition is a 3D-imaging and navigation platform for accelerating lung cancer diagnosis and treatment by combining CT-like 3D images acquired at the tableside with live X-ray guidance and other tools to support image-guided lung procedures, according to a news release.
Azurion Lung Edition uses Philips’ Cone Beam CT scans and is designed specifically for bronchoscopy procedures, Philips said, allowing clinicians to perform minimally invasive endobronchial biopsies and lesion ablation during the same procedure.
Philips said the platform expands the role of image-guided interventions and has been adopted around the world, being put to use in over 2 million procedures. The Azurion Lung Edition is now available in the U.S.
“Image-guided minimally invasive procedures continue to expand into new treatment areas, enabled by sophisticated, procedure-oriented solutions like Azurion Lung Edition,” Philips image-guided therapy chief medical officer Dr. Atul Gupta said in the release. “With lung cancer increasingly being detected at an earlier stage, new minimally invasive treatment strategies like ablation have the potential to significantly improve outcomes for patients.”
